InVision Precision Cardiac Amyloid vs Impala
AI Verdict
Choose InVision Precision Cardiac Amyloid if…
Choose InVision Precision Cardiac Amyloid if your cardiology lab requires AI-powered software to specifically enhance the detection of cardiac amyloidosis from echocardiogram studies. This tool is ideal for integrating into existing echocardiography workflows to improve diagnostic precision for this often underdiagnosed, life-threatening condition, supporting earlier intervention and better patient outcomes.
View InVision Precision Cardiac Amyloid →Choose Impala if…
Choose AliveCor's Impala if your healthcare setting needs a portable, AI-powered 12-Lead ECG device for rapid cardiac assessment in various clinical environments. This tool is best suited for situations demanding quick, on-the-spot detection of acute, life-threatening cardiac conditions, such as heart attacks, leveraging a simplified leadset for efficient and timely use by healthcare professionals.
View Impala →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | InVision Precision Cardiac Amyloid | Impala |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud or on-premise | Portable device, integrated with mobile applications/platforms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ImpalaImpala's portable design with a reduced leadset and single cable simplifies ECG acquisition, making it highly usable for rapid assessment by a broader range of healthcare professionals, even those with infrequent ECG experience. InVision, while integrating into existing workflows, doesn't offer the same level of simplified physical interaction for data acquisition.
Clinical Value
InVision Precision Cardiac AmyloidInVision Precision Cardiac Amyloid focuses on the early detection of a specific, life-threatening, and often underdiagnosed condition (cardiac amyloidosis) with strong evidence, including peer-reviewed publications in high-impact journals like JAMA Cardiology and Nature, and FDA Breakthrough Device Designation. Impala provides a broader, rapid assessment for various cardiac conditions, but Tool A's targeted approach to a complex diagnostic challenge with robust validation stands out.
Pricing & Value
InVision Precision Cardiac AmyloidInVision Precision Cardiac Amyloid offers transparent starting pricing at $49/month and explicitly mentions a direct reimbursement path with CPT code 0932T, effective January 1, 2025. In contrast, AliveCor's Impala requires contacting them for pricing, which offers less transparency for potential customers.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness. Tool A is a SaMD designed for seamless integration into existing echocardiography lab workflows and has FDA clearance and HIPAA compliance. Tool B is also FDA cleared and HIPAA compliant with a BAA, and AliveCor has a track record of EHR integration and supporting clinical trials, indicating its suitability for broader enterprise deployment.
Innovation
ImpalaImpala's innovation lies in its ability to acquire a full diagnostic-quality 12-lead ECG using a significantly reduced leadset and a single cable, powered by AI, making it highly portable and efficient for rapid assessment in various settings. While InVision's AI for cardiac amyloidosis is also innovative, Impala's approach to simplifying a complex diagnostic procedure (12-lead ECG) for broader accessibility represents a more transformative innovation in device design and functionality.
Support & Docs
ImpalaAliveCor (Tool B) provides comprehensive support resources, including user manuals, FAQs, and direct contact options via phone and email, along with an AI-powered virtual assistant for 24/7 guidance. InVision Medical Technology (Tool A) does not have readily available, specific support documentation or dedicated customer service channels publicly detailed for its Precision Cardiac Amyloid product in the search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | InVision Precision Cardiac Amyloid | Impala |
|---|---|---|
| Name | InVision Precision Cardiac Amyloid | Impala |
| Company | InVision Medical Technology Corporation | AliveCor |
| Description | AI-powered software for echocardiography to detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and improved patient outcomes. | AliveCor's 'Impala' (FDA K232035) is a portable, AI-powered 12-Lead ECG device for healthcare professionals, not a physician directory tool. AliveCor specializes in cardiac monitoring solutions. |
| Primary Function | AI-powered detection of cardiac amyloidosis from echocardiograms | Portable 12-Lead ECG acquisition and AI-powered cardiac determinations |
| Key Feature 1 | AI-powered detection of cardiac amyloidosis | Portable 12-Lead ECG acquisition |
| Key Feature 2 | Evaluation of transthoracic echocardiogram studies (apical-4-chamber and parasternal-long-axis view videos) | Acquires 4 standard diagnostic-bandwidth leads (I, II, V1 or V2, V4) |
Videos
Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and Impala.
Frequently Asked Questions
More Comparisons
More matchups featuring InVision Precision Cardiac Amyloid or Impala
Backers
Who funded each tool's parent company.